AstraZeneca reports positive data from Phase III trial of efzimfotase alfa

AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia ...
Antelope Valley Press

The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China

Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W.

AstraZeneca scores pediatric win while adult trial falls short in rare bone disease

AstraZeneca Plc AZN released topline data from the Phase 3 program for efzimfotase alfa (ALXN1850) in the broad ...
Pharmabiz

Efzimfotase alfa demonstrated positive results from global phase III clinical programme in hypophosphatasia

Efzimfotase alfa demonstrated positive results from global phase III clinical programme in hypophosphatasia: Cambridge, UK Wednesday, April 1, 2026, 10:00 Hrs [IST] The efzimfotas ...
pharmaphorum

AZ considers filings for long-acting Strensiq follow-up

AstraZeneca's Alexion unit is planning to file a new, long-acting follow-up to its Strensiq therapy for ultra-rare disease ...
Business Wire

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration ...